VoxNeuro Announces Collaboration with Boston University and Launch of Clinical Studies Focusing on Concussion and Alzheimer’s Disease

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

VoxNeuro, a Software as a Medical Device (SaMD) brain health company that analyzes brain-based biomarkers to assess cognitive function, recently announced a research partnership with Boston University and the launch of Clinical Studies Focusing on mild-Traumatic Brain Injury/Concussion and Alzheimer's disease.

VoxNeuro, in partnership with Boston University, has launched two studies that will evaluate its cognitive health assessment platform in an outpatient setting to assess diagnostic accuracy. The studies will focus on patients suffering from mild-Traumatic Brain Injury (mTBI)/Concussion and Alzheimer’s disease, respectively.

VoxNeuro is an OBIO® member.

Arsheen Kaur
Previous

Oncoustics AI and UHN Awarded OBIO® Early Adopter Health Network Grant to Trial Point of Care Liver Assessment Solutions in Clinic
Next

Linamar MedTech Achieves ISO 13485 Certification for Medical Device Manufacturing